Neuraxis (NRXS) director receives 26K-share stock grant

Rhea-AI Filing Summary

Keyser Jane Elizabeth reported acquisition or exercise transactions in this Form 4 filing.

Neuraxis, Inc. director Jane Elizabeth Keyser reported an award of 26,073 shares of Common Stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for her services as an independent director. Following this grant, her direct holdings total 72,408 shares of Neuraxis common stock.

Insider Trade Summary

Net Buyer: 26,073 shares

Net Buy 1 txn

Insider Keyser Jane Elizabeth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	26,073	$6.28	$164K

Holdings After Transaction: Common Stock — 72,408 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

Key Figures

Shares granted: 26,073 shares Grant value per share: $6.28 per share Shares owned after transaction: 72,408 shares

3 metrics

Shares granted 26,073 shares Common Stock award to independent director on 2026-08-13

Grant value per share $6.28 per share Reported value for the 26,073-share stock award

Shares owned after transaction 72,408 shares Director’s direct Neuraxis common stock holdings after the grant

Key Terms

independent director, Common Stock, Grant, award, or other acquisition

3 terms

independent director financial

"compensation for services as independent director of the Issuer"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Common Stock financial

"These shares of common stock were issued to the reporting person"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

FAQ

What insider transaction did NRXS director Jane Elizabeth Keyser report?

Jane Elizabeth Keyser reported a from Neuraxis, Inc. on 2026-08-13. The shares were issued as compensation for her services as an independent director rather than a market purchase.

At what value were the NRXS shares granted to Jane Elizabeth Keyser?

The awarded shares were valued at $6.28 per share on 2026-08-13. This figure represents the reported per-share value used for the grant of 26,073 Neuraxis common shares.

How many NRXS shares does Jane Elizabeth Keyser hold after this transaction?

After the grant, Jane Elizabeth Keyser holds 72,408 shares of Neuraxis common stock directly. This total reflects the post-transaction holdings reported in the Form 4 filing for 2026-08-13.

Was the August 13, 2026 NRXS insider transaction a market buy or compensation grant?

The August 13, 2026 transaction was a compensation grant, not a market purchase. Neuraxis issued 26,073 shares of common stock to director Jane Elizabeth Keyser for her services as an independent director.

Is Jane Elizabeth Keyser’s NRXS Form 4 transaction under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed. The grant of 26,073 shares is reported as compensation for independent director services, rather than as a trade executed under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 06:33 PM Accepted by SEC EDGAR 08/17/2026 - 06:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keyser Jane Elizabeth

(Last) (First) (Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL INDIANA 46032

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		A		26,073(1)	A	$6.28(1)	72,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

	/s/ Beth Keyser	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)